3rd Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis

Release Date: September 28, 2021
Expiration Date: September 28, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in myeloproliferative neoplasms (MPNs), considering case studies and applying recent clinical trial data to real-world scenarios. This activity will serve as an update on the emerging trends in diagnosis, risk stratification, and treatment of myelofibrosis and polycythemia vera.

This educational activity is an archive of the live virtual symposium held on September 23, 2021.

Acknowledgement of Commercial Support

This educational activity is supported by educational grants from: AbbVie Inc, Incyte Corporation, PharmaEssentia USA Corporation, and Protagonist Therapeutics.

Target Audience

This educational activity is directed toward hematologists and medical oncologists as well as fellows involved in the treatment and management of patients with myeloproliferative neoplasms (MPNs). Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of MPNs may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain clinical, cytogenetic, and mutation characteristics of MPNs and the potential impact of these factors on risk stratification and treatment decision-making
• Discuss current strategies for managing patients across the spectrum of MPNs, including those with myelofibrosis (MF) and polycythemia vera (PV)
• Identify patients with MF and PV who may benefit from participation in clinical trials based on individual and disease characteristics
• Implement multidisciplinary strategies to mitigate and manage treatment-related toxicities and disease-related symptoms

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Ronald Hoffman, MD
Albert A. and Vera G. List Professor of Medicine
Director, Myeloproliferative Disorders Research Program
Tisch Cancer Institute
Icahn School of Medicine
New York, NY

Disclosures: Ronald Hoffman, MD, has no relevant financial relationships with ineligible companies.

Kathryn Johnson, DNP, MSc, FNP-BC
Clinical Program Manager
Myeloproliferative Neoplasms Program
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Kathryn Johnson, DNP, MSc, FNP-BC; has no relevant financial relationships with ineligible companies.

Marina Kremyanskaya MD, PhD
Assistant Professor
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Marina Kremyanskaya, MD, PhD, has no relevant financial relationships with ineligible companies.

Naveen Pemmaraju, MD
Associate Professor, Department of Leukemia
Director, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Affymetrix, SagerStrong Foundation, Novartis Pharmaceuticals, Stemline Therapeutics, Samus Therapeutics, AbbVie, Cellectis, Daiichi Sankyo, Plexxikon; Consultant: Pacylex Pharmaceuticals, ImmunoGen, Bristol Myers Squibb, Blueprint Medicines, ClearView Healthcare Partners, Astellas Pharma, Incyte Corporation, Novartis Pharmaceuticals, LFB Biotechnologies, Stemline Therapeutics, Celgene Corporation, AbbVie, Mustang Bio, Roche Diagnostics, DAVA Oncology; Other (Travel): Stemline Therapeutics, Celgene Corporation, Mustang Bio, DAVA Oncology, AbbVie.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.